Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Melanoma × irofulven × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Rectal Neoplasms 2 Pancreatic Neoplasms 2 Colorectal Neoplasms 2 Colonic Neoplasms 2 Carcinoma, Ovarian Epithelial 2 Uterine Cervical Neoplasms 1 Unspecified Childhood Solid Tumor, Protocol Specific 1 Thyroid Neoplasms 1 Stomach Neoplasms 1 Prostatic Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Ovarian Neoplasms 1 Oligodendroglioma 1 Myelodysplastic Syndromes 1 Melanoma 1 Lung Neoplasms 1 Liver Neoplasms 1 Leukemia, Myeloid, Acute 1 Leukemia 1 Kidney Neoplasms 1 Gliosarcoma 1 Glioblastoma 1 Fallopian Tube Neoplasms 1 Endometrial Neoplasms 1 Central Nervous System Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms, Male 1 Breast Neoplasms 1 Brain Neoplasms 1

Interventions

pembrolizumab 268 Nivolumab 241 Ipilimumab 221 aldesleukin 126 Cyclophosphamide 125 Interleukin-2 92 trametinib 76 dabrafenib 68 Dacarbazine 68 Temozolomide 65 Vemurafenib 64 fludarabine 63 fludarabine phosphate 56 Biopsy 45 Radiosurgery 43 Bevacizumab 40 sargramostim 39 binimetinib 38 incomplete Freund's adjuvant 36 Paclitaxel 35 atezolizumab 34 Cisplatin 34 Radiotherapy 33 encorafenib 32 Magnetic Resonance Spectroscopy 32 Blood Specimen Collection 32 cobimetinib 31 Specimen Handling 31 Introns 31 Carboplatin 29

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00005968 2013-05-30

Irofulven in Treating Patients With Stage IV Melanoma

University of Colorado, Denver

Phase 2 Completed

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡